Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EUK-134 是合成的超氧化物歧化酶和过氧化氢酶模拟物,可保护大鼠肾脏免受缺血再灌注引起的损伤。它作用于 H9C2 细胞,降低NF-κB 表达、MDA 水平和蛋白质羰基化。它是具有过氧化氢酶活性的超氧化物歧化酶 (SOD) 模拟物 (SODm)。它是保护有丝分裂的抗氧化剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 139 | 现货 | ||
2 mg | ¥ 183 | 现货 | ||
5 mg | ¥ 279 | 现货 | ||
10 mg | ¥ 396 | 现货 | ||
25 mg | ¥ 683 | 现货 | ||
50 mg | ¥ 1,070 | 现货 | ||
100 mg | ¥ 1,650 | 现货 | ||
200 mg | ¥ 2,460 | 现货 | ||
500 mg | ¥ 3,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 237 | 现货 |
产品描述 | EUK-134, a synthetic superoxide dismutase (SOD)/catalase mimetic, exhibits potent antioxidant activities, and inhibits the formation of β-amyloid and related amyloid fibril. |
体外活性 | EUK 134 shows potent catalase and SOD activities, and protects human fibroblasts against cytotoxicity by glucose and glucose oxidase. [1] EUK 134 (20 μM) prevents Aβ-induced microglial proliferation in vitro. [2] In SK-N-MC cells, EUK134 protects neuronal cells against H(2)O(2) toxicity by attenuating oxidative stress through inhibition of MAPK pathway, and also results in decreased expression of pro-apoptotic genes p53 and Bax as well as enhanced expression of anti-apoptotic Bcl-2 gene. [3] EUK 134 significantly inhibits amyloid formation at two molar ratios of 1:1 and 5:1 (drugs to protein). [4] |
体内活性 | EUK 134 (2.5 mg/kg), in a middle cerebral artery occlusion model, significantly reduces brain infarct size, and apparently prevents further infarct growth. [1] EUK-134 prevents oxidative stress and attenuates rat brain damage induced by systemic administration of systemic kainic acid (KA). [5] |
别名 | EUK 134, 乙基双亚氨基甲基愈创木酚锰氯化物 |
分子量 | 416.74 |
分子式 | C18H18ClMnN2O4 |
CAS No. | 81065-76-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 77 mg/mL (184.8 mM)
H2O: 11 mg/mL (26.4 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.3996 mL | 11.9979 mL | 23.9958 mL | 59.9894 mL |
5 mM | 0.4799 mL | 2.3996 mL | 4.7992 mL | 11.9979 mL | |
10 mM | 0.24 mL | 1.1998 mL | 2.3996 mL | 5.9989 mL | |
20 mM | 0.12 mL | 0.5999 mL | 1.1998 mL | 2.9995 mL | |
DMSO | 50 mM | 0.048 mL | 0.24 mL | 0.4799 mL | 1.1998 mL |
100 mM | 0.024 mL | 0.12 mL | 0.24 mL | 0.5999 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
EUK-134 81065-76-1 Neuroscience Beta Amyloid Inhibitor Free mitoprotective Nephrotoxicity antioxidant SODm species EUK 134 Nuclear factor-kappaB NRK-52E radicals NF-κB inhibit oxygen Nuclear factor-κB 乙基双亚氨基甲基愈创木酚锰氯化物 catalase Reactive EUK134 Superoxide mimetic SOD dismutase inhibitor